5 Results

People

  1. Diani
    Diani
  2. Fernandez
    Fernandez
  3. Livingston
    Livingston
  4. Ragupathi
    Ragupathi
  5. Scher
    Scher
  6. Slovin
    Slovin
  7. Bekele
    Bekele
  8. Brown
    Brown
  9. Danishefsky
    Danishefsky
  10. Dao
    Dao

Groups

  1. Department of Medicine (4)
  2. Hematologic Malignancies, Division of (3)
  3. Melanoma and Immunotherapeutics Service (3)
  4. Solid Tumor Oncology Division (3)
  5. GSK Faculty (2)
  6. Genitourinary Oncology Service (2)
  7. Melanoma Disease Management Team (2)
  8. Molecular Pharmacology and Chemistry Program Faculty (2)
  9. Sloan Kettering Institute Faculty (2)
  10. Adult Leukemia (1)
  1. "middle aged"
  2. "Springer"
  3. "Cancer Immunology, Immunotherapy"
  4. "Journal article"
Formats
  1. Journal Article (5)
Groups
  1. Department of Medicine (4)
  2. Hematologic Malignancies, Division of (3)
  3. Melanoma and Immunotherapeutics Service (3)
  4. Solid Tumor Oncology Division (3)
  5. GSK Faculty (2)
  6. Genitourinary Oncology Service (2)

More Groups

People
  1. Celina Fernandez (2)
  2. Govindaswami Ragupathi (2)
  3. Howard Scher (2)
  4. Meghan Diani (2)
  5. Philip Livingston (2)
  6. Susan Slovin (2)

More People

Years
  1. 2022 (1)
  2. 2010 (1)
  3. 2007 (1)
  4. 2006 (1)
  5. 2005 (1)
Publications
  1. Cancer Immunology, Immunotherapy (5)
Publishers
  1. Springer (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: A prospective cohort study
    Journal Article

    Fujita, K.; Elkington, P.; Redelman-Sidi, G.; Kanai, O.; Yamamoto, Y.; Imakita, T.; Okamura, M.; Nakatani, K.; Mio, T.
    Cancer Immunology, Immunotherapy (2022)

    Fulltext@MSK | Save
  • WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
    Journal Article

    Krug, L. M.; Dao, T.; Brown, A. B.; Maslak, P.; Travis, W.; Bekele, S.; Korontsvit, T.; Zakhaleva, V.; Wolchok, J.; Yuan, J.; more...
    Cancer Immunology, Immunotherapy (2010)

    Fulltext@MSK | Save
  • A polyvalent vaccine for high-risk prostate patients: "Are more antigens better?"
    Journal Article

    Slovin, S. F.; Ragupathi, G.; Fernandez, C.; Diani, M.; Jefferson, M. P.; Wilton, A.; Kelly, W. K.; Morris, M.; Solit, D.; Clausen, H.; more...
    Cancer Immunology, Immunotherapy (2007)

    Fulltext@MSK | Save
  • Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells
    Journal Article

    Fay, J. W.; Palucka, A. K.; Paczesny, S.; Dhodapkar, M.; Johnston, D. A.; Burkeholder, S.; Ueno, H.; Banchereau, J.
    Cancer Immunology, Immunotherapy (2006)

    Fulltext@MSK | Save
  • Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: Clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer
    Journal Article

    Slovin, S. F.; Ragupathi, G.; Musselli, C.; Fernandez, C.; Diani, M.; Verbel, D.; Danishefsky, S.; Livingston, P.; Scher, H. I.
    Cancer Immunology, Immunotherapy (2005)

    Fulltext@MSK | Save